Breaking News Instant updates and real-time market news.

CIEN

Ciena

$37.98

(0.00%)

, MA

MasterCard

$238.90

(0.00%)

09:40
04/15/19
04/15
09:40
04/15/19
09:40

Unusually active option classes on open April 15th

Unusual total active option classes on open include: Ciena (CIEN), Mastercard (MA), UnitedHealth (UNH), Goldman Sachs (GS), Nokia (NOK), NIO Inc (NIO), Las Vegas Sands (LVS), Merck (MRK), Chevron (CVX), and Wells Fargo (WFC).

CIEN

Ciena

$37.98

(0.00%)

MA

MasterCard

$238.90

(0.00%)

UNH

UnitedHealth

$223.17

(0.00%)

GS

Goldman Sachs

$207.86

(0.00%)

NOK

Nokia

$5.94

(0.00%)

NIO

NIO Inc.

$4.99

(0.00%)

LVS

Las Vegas Sands

$66.87

(0.00%)

MRK

Merck

$79.40

(0.00%)

CVX

Chevron

$119.82

(0.00%)

WFC

Wells Fargo

$46.49

(0.00%)

  • 15

    Apr

  • 15

    Apr

  • 16

    Apr

  • 17

    Apr

  • 17

    Apr

  • 23

    Apr

  • 26

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 07

    May

  • 18

    May

  • 20

    May

  • 22

    May

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 17

    Jun

  • 20

    Jun

  • 25

    Jun

  • 13

    Jul

  • 16

    Jul

  • 16

    Jul

  • 06

    Aug

  • 20

    Sep

  • 12

    Oct

CIEN Ciena
$37.98

(0.00%)

03/06/19
MKMP
03/06/19
NO CHANGE
Target $49
MKMP
Buy
Ciena price target raised to $49 from $45 at MKM Partners
MKM Partners analyst Michael Genovese raised his price target on Ciena to $49 and kept his Buy rating after its "clean" beat in Q1 and a raise in its FY19 revenue outlook to the top of the prior forecast range. The analyst sees the company "gaining share in both Telco and non-Telco accounts on the strength of its best-in-class Optical engine technology" and also cites the management's confidence ahead of the WaveLogic product launch. Genovese believes that Ciena can grow its FY19 revenues by high single digits again as U.S. Tier 1 telco momentum swings from decline to growth.
03/06/19
RILY
03/06/19
NO CHANGE
Target $48
RILY
Buy
Ciena price target raised to $48 from $42.50 at B. Riley FBR
B. Riley FBR analyst Dave Kang raised his price target for Ciena to $48 saying broad strength across product and geographies continues to drive momentum. He keeps a Buy rating on the shares following last night's fiscal Q1 results.
03/27/19
MSCO
03/27/19
NO CHANGE
MSCO
Morgan Stanley upgrades Lumentum, downgrades Acacia in optical ratings shake up
As previously reported, Morgan Stanley analyst Meta Marshall upgraded Lumentum (LITE) to Overweight from Equal Weight and downgraded Acacia Communications (ACIA) to Underweight from Equal Weight as she believes thematic transitions in the optical sector are being misvalued in the market. On Lumentum, she thinks 3D sensing estimates should be reset and believes the remainder of the year presents more opportunity for upside. Marshall raised her price target on Lumentum shares to $65 from $55. On Acacia, Marshall thinks investors are over-extrapolating its earnings power and not assigning enough risk to customer concentration. However, the analyst raised her price target on Acacia shares to $44 from $38, noting that she is early with her downgrade and believes the company could "post meaningful beats" in the next 6-9 months. Outside of these two outlier ratings, Marshall has an Equal Weight rating on optical components providers Infinera (INFN), II-VI (IIVI) and Ciena (CIEN).
04/15/19
NORL
04/15/19
UPGRADE
NORL
Outperform
Ciena upgraded to Outperform from Market Perform at Northland
MA MasterCard
$238.90

(0.00%)

04/15/19
PIPR
04/15/19
NO CHANGE
PIPR
Piper says FinTech secular drives 'remain strong' into Q1 results
While absolute and relative valuations in FinTech are back near the all-time highs, the Federal Reserve "has moved from a headwind last Fall to a Neutral factor for economic growth and equity valuations," Piper Jaffray analyst Jason Deleeuw tells investors in a research note. Also, the ongoing secular drivers for FinTech "remain strong" as global payments and business ecosystems digitize, says the analyst. He remains constructive on FinTech names heading into Q1 earnings and also tells investors to look at some mortgage/real estate services stocks. Deleeuw's top ideas are Black Knight (BKI), Redfin (RDFN), Euronet (EEFT) and Cannae Holdings (CNNE). He also boosted his price target for Overweight-rated Euronet to $171 from $159, for Overweight-rated Global Payments (GPN) to $163 from $152, for Overweight-rated MasterCard (MA) to $272 from $262, for Neutral-rated PayPal (PYPL) to $104 from $97, for Overweight-rated Visa (V) to $191 from $178 and for Neutral-rated Worldpay (WP) to $115 from $101.
04/11/19
NOMU
04/11/19
NO CHANGE
Target $175
NOMU
Buy
Visa price target raised to $175 from $151 at Nomura Instinet
Nomura Instinet analyst Bill Carcache raised his price target for Visa (V) to $175 from $151 ahead of the company's Q1 results. Visa does not deserve to trade at a "2.5 turn discount" to MasterCard (MA) when it is generating revenue growth that is on par, Carcache tells investors in a research note. While Visa "is certainly less emphatic" about its long-term growth prospects, its growth potential isn't "meaningfully different" and its valuation multiple should "grind its way closer" to MasterCard's over time, says the analyst. He keeps a Buy rating on both stocks.
04/05/19
LOOP
04/05/19
NO CHANGE
LOOP
Buy
MasterCard, Visa may benefit from China trade deal, says Loop Capital
Loop Capital analyst Joseph Vafi speculates that the U.S.-China trade deal could be a positive for MasterCard (MA) and Visa (V), neither of which has any "material" operations in China at this time, by resolving the countries' intellectual property dispute. The analyst notes that Chinese negotiators appear to be "somewhat willing" to negotiate the IP issue, and a concession allowing U.S. firms to operate on the mainland without a local partner could "grease the skids for eventual approval of domestic business licenses" for payment networks. Vafi is keeping a Buy rating on both MasterCard and Visa with unchanged price targets of $232 and $157 respectively.
04/11/19
WELS
04/11/19
NO CHANGE
Target $270
WELS
Outperform
MasterCard price target raised to $270 from $238 at Wells Fargo
Wells Fargo analyst Donald Fandetti raised his price target for MasterCard to $270 from $238 ahead of quarterly results as he believes his covered card companies will show slightly improving consumer trends this quarter. The analyst reiterates an Outperform rating on the shares.
UNH UnitedHealth
$223.17

(0.00%)

04/01/19
PIPR
04/01/19
NO CHANGE
PIPR
Overweight
Myriad traded lower on 'minor' United Healthcare change, says Piper Jaffray
Shares of Myriad Genetics closed Friday down 4% after United Healthcare (UNH) added a Current Procedural Terminology code and simplified the coverage rationale on its existing medical policy for pharmacogenetics, Piper Jaffray analyst William Quirk tells investors in a research note. The updated policy does not include a review of the Genesight dossier/Guided study, says the analyst. He views the change at United Healthcare as "minor" and keeps an Overweight rating on Myriad Genetics. Quirk continues to look for positive Genesight coverage.
04/10/19
CANT
04/10/19
NO CHANGE
CANT
Senate hearing a net positive for PBMs, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper views yesterday's Senate hearing as a net positive for the pharmacy benefit managers. The PBMs represented were Cigna (CI), CVS Health (CVS), UnitedHealth (UNH), Humana (HUM) and Prime Therapeutics. Although the Senators were not supportive of the PBMs, the executives responded well to questions and put forth a solid effort to address concerns regarding their business model and incentives, Halper tells investors in a research note. Overall, he views the hearing as a net positive for PBMs "as the group was able to counter the negative sentiment with constructive responses, recognizing this story is far from over."
03/21/19
RAJA
03/21/19
UPGRADE
Target $8
RAJA
Outperform
Raymond James upgrades Diplomat Pharmacy, sees number of potential suitors
Raymond James analyst John Ransom upgraded Diplomat Pharmacy (DPLO) to Outperform from Market Perform with an $8 price target. The stock closed yesterday up 14c to $5.86. Following the 56% share decline since the February earnings delay, Diplomat would represent value to a strategic buyer, Ransom tells investor in a research note. The analyst sees a number of potential buyers that would "covet" Diplomat Pharmacy's infusion franchise and could fold its large mail order business into an existing platform, including UnitedHealth (UNH), Cigna (CI), CVS Health (CVS), Anthem (ANTM) and Centene (CNC). Ransom thinks Diplomat's current fundamentals should motivate its board to step up its assessment of strategic options. He believes the company's collection of assets are underappreciated at current valuation levels.
04/02/19
JEFF
04/02/19
UPGRADE
Target $107
JEFF
Buy
Quest, LabCorp upgraded to Buy ahead of UnitedHealth lab network rollout
Jefferies analyst Brian Tanquilut upgraded both Quest Diagnostics (DGX) and Laboratory Corp. of America (LH) to Buy from Hold on the belief that UnitedHealth's (UNH) rollout on July 1 of its preferred lab network will be a positive catalyst for both stocks. Quest and LabCorp's likely inclusion should bolster their organic growth beginning in 2020, Tanquilut tells investors in a research note. The analyst finds both stocks "compelling" with their 2019 outlooks "seemingly de-risked with fairly conservative guidance ranges" and 2020 consensus estimates "looking conservative." Further, Quest's and LabCorp's valuations are at below-historical relative averages, Tanquilut contends. The analyst raised his price target for Laboratory Corp. to $190 from $154 and for Quest to $107 from $93.
GS Goldman Sachs
$207.86

(0.00%)

02/21/19
02/21/19
INITIATION

Odeon's Dick Bove starts Goldman Sachs with Sell rating
Odeon analyst Dick Bove initiated coverage of Goldman Sachs with a Sell rating. Now is not the time to own the stock as indications are growing that Goldman's legal issues "are just beginning related to the events in Malaysia," Bove tells investors in a research note. The analyst adds that the Federal Reserve and U.S. Justice Department are also investigating these events and that fines are expected. Goldman Sachs in late morning trading is down $2.00 to $196.60.
03/01/19
SBSH
03/01/19
NO CHANGE
SBSH
Neutral
Goldman Sachs faces 'tough legal setup' in 1MDB case, says Citi
Goldman Sachs' alleged role in the ongoing 1MDB scandal has weighed on the stock since November, Citi analyst Keith Horowitz tells investors in a research note. After researching the case and speaking with a subject matter expert, the analyst thinks Goldman "faces a tough legal setup" in the 1MDB case. He expects the company to settle with regulators and estimates a range of penalties from $1.5B to $9.0B, with a base case of $4B-$5B. He sees suspended business activities as unlikely. Despite the 14% underperformance since November, Goldman shares are fairly valued given continued 1MDB overhang, Horowitz tells investors in a research note. He keeps a Neutral rating on the shares.
03/26/19
WEDB
03/26/19
NO CHANGE
WEDB
Apple Card 'a slight negative' for Visa, says Wedbush
Wedbush analyst Moshe Katri believes Apple's announcement of a physical Apple card is a "slight negative" for Outperform rated Visa (V) and a "slight positive" for Outperform rated MasterCard (MA), assuming it gains traction. The physical Apple card is a partnership with Goldman Sachs (GS) and Mastercard.
03/25/19
JEFF
03/25/19
NO CHANGE
JEFF
Jefferies downgrades Financials to Underweight on 'shocking' Fed meeting
Jefferies analyst Steven DeSanctis is "very surprised" by last week's Federal Reserve's decision taking rate hikes completely off table in 2019. The "shocking" Fed meeting means lower rates for longer, which is not good for Financials, DeSanctis tells investors in a research note. A "lack of catalysts and weaker earnings growth" going forward for the entire sector, not just banks, means an Underweight rating on the space makes sense, says the analyst. As such, he downgraded his rating on the Financial sector to Underweight from Market Weight. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
NOK Nokia
$5.94

(0.00%)

04/15/19
GSCO
04/15/19
DOWNGRADE
Target $5.5
GSCO
Sell
Goldman sees risks to Nokia estimates, downgrades shares to Sell
Goldman Sachs analyst Alexander Duval downgraded Nokia (NOK) to Sell from Neutral and cut his price target for the shares to $5.50 from $6.40. Consensus estimates have further downside as analysts factor in lower Networks revenues, a more conservative margin trajectory and "more muted" growth in the Nokia's "highly profitable" Patents business, Duval tells investors in a research note. The analyst reduced his Networks growth rate on "subseasonal" growth in the first half of 2019 as well as management's "cautious" statements. Duval says these contrast with his industry discussions suggesting a wireless market growth inflection, due to 5G. He sees risks to Nokia's market share "given newsflow implying share gains by its main competitor, Ericsson" (ERIC).
03/20/19
NORD
03/20/19
DOWNGRADE
NORD
Hold
Nokia downgraded to Hold from Buy at Nordea
03/26/19
MKMP
03/26/19
NO CHANGE
Target $8
MKMP
Buy
Nokia a top pick for 'steadily moving forward' 5G market, says MKM Partners
MKM Partners analyst Michael Genovese kept his Buy rating and $8 price target on Nokia (NOK), maintaining his view of the company as the "top pick for 5G", which he sees as "steadily moving forward". The analyst notes that the stock outperformed the Nasdaq by 10% over the past 6 months but underperformed the index by 8% over the past 3 months on investors perceptions that the rollout is proceeding slowly. Genovese adds that the most recent headwinds of wrongdoing in the company's Alcatel-Lucent transactions are unlikely to be material, and maintains that Nokia should be favored over Ericson (ERIC) in 5G because of its "greater exposure to IP Routing, Optical and Wireline".
04/15/19
GSCO
04/15/19
DOWNGRADE
Target $5.5
GSCO
Sell
Nokia downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Alexander Duval downgraded Nokia to Sell from Neutral and cut his price target for the shares to $5.50 from $6.40.
NIO NIO Inc.
$4.99

(0.00%)

04/04/19
SBSH
04/04/19
UPGRADE
Target $6.8
SBSH
Buy
NIO Inc. upgraded to Buy from Neutral at Citi
Citi analyst Jeff Chung upgraded NIO Inc. to Buy from Neutral while lowering his price target for the shares to $6.80 from $7.20.
04/04/19
04/04/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris saying investors will continue to gain comfort with the incremental financial risk created by Facebook's content and privacy concerns. 2. NIO Inc. (NIO) upgraded to Buy from Neutral at Citi and to Neutral from Underperform at BofA/Merrill. 3. Ingersoll-Rand (IR) upgraded to Buy from Neutral at BofA/Merrill with analyst Andrew Obin citing premium core and earnings growth. 4. EOG Resources (EOG) upgraded to Buy from Hold at Tudor Pickering. 5. Signature Bank (SBNY) upgraded to Overweight from Neutral at JPMorgan with analyst Steven Alexopoulos raising his price target for the shares to $150 from $133. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/19
BOFA
04/04/19
UPGRADE
Target $6.2
BOFA
Neutral
NIO Inc. upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Ming Hsun Lee upgraded NIO Inc. to Neutral from Underperform with a price target of $6.20. The shares, after declining 47% from the peak in early March, have now factored in the company's lowered sales volume growth, Lee tells investors in a research note. The analyst views NIO's current valuation as fair and expects its volume sales to grow sequentially in Q2 relative to Q1. The company just launched a six-seater ES8, which should gain some popularity from consumers, says Lee. Further, NIO is arranging more test-drive events in more cities, which the analyst believes should help orders improve.
04/04/19
SBSH
04/04/19
UPGRADE
Target $6.8
SBSH
Buy
Citi upgrades NIO to Buy after 47% selloff since March peak
Citi analyst Jeff Chung upgraded NIO Inc. to Buy from Neutral while lowering his price target for the shares to $6.80 from $7.20. BofA/Merrill this morning also upgraded the shares to Neutral from Underperform. Chung is in part making a valuation call with the shares down 47% since the early-March peak. He also expects a valuation "re-rate" of China's electric vehicle sector. NIO's Q1 shipments beat consensus and ES6 deliveries, which start in early June, should be faster than consensus expects, Chung tells investors in a research note. The analyst also believes NIO's customer base is less price sensitive due to its premium brand positioning. Share of NIO are up 14c to $5.45 in premarket trading.
LVS Las Vegas Sands
$66.87

(0.00%)

04/08/19
JEFF
04/08/19
UPGRADE
Target $170
JEFF
Buy
Jefferies upgrades Wynn Resorts to Buy on better outlook for Macau and China
Jefferies analyst David Katz upgraded Wynn Resorts (WYNN) to Buy from Hold following better than expected gross gaming revenue results from Macau for March and signs that suggest to him that it is reasonable to expect economic improvement throughout 2019 in China. Katz, who raised his Macau market forecast to 10.0% GGR growth from 5.3%, also noted that concerns about the concessions there have recently eased due to MGM/SJM having received a concession extension to 2022 with a nominal fee and Las Vegas Sands (LVS) having signed an agreement in Singapore for extended market exclusivity to 2030. While Katz considers a wide range of financial outcomes for Wynn's license investigation hearings in Massachusetts, he believes they are more positively skewed given that the property is nearly completed, he added. Katz raised his price target for Wynn shares to $170 from $119.
04/08/19
JEFF
04/08/19
NO CHANGE
Target $69
JEFF
Hold
Las Vegas Sands price target raised to $69 from $57 at Jefferies
Jefferies analyst David Katz raised his price target for Las Vegas Sands to $69 from $57 citing the better than expected results and an improved outlook on Macau. The analyst says his Macau estimates are now modestly above consensus expectations and warrant higher multiples. Ultimately, however, he thinks the shares "reflect a meaningful portion of this upside." Katz keeps a Hold rating on Las Vegas Sands in a research note titled "How to Lose Some Risk in 20 Days."
03/20/19
FBCO
03/20/19
INITIATION
Target $58
FBCO
Neutral
Las Vegas Sands assumed with a Neutral at Credit Suisse
Credit Suisse analyst Ben Combes assumed coverage of Las Vegas Sands with a Neutral rating and $58 price target.
03/06/19
MSCO
03/06/19
NO CHANGE
MSCO
Morgan Stanley raises Macau casino operator targets on higher mass forecast
Morgan Stanley analyst Thomas Allen said that Morgan Stanley is increasingly bullish that China's policy stimulus is working as a firm, adding that he now expects Macau gross gaming revenue to grow 1% in 2019, up from his prior forecast for a 2% decline. Underpinning that improved view, he has raised his mass market growth forecast to 7% from 2%, citing accelerated visitation growth following the HKZM bridge opening as well as the firm's currency strategists' call for the CNY to continue to appreciate against the USD. While he still has an "in-line" view on Macau, Allen raised his price target on Las Vegas Sands (LVS) to $66 from $64, his target on Wynn (WYNN) to $130 from $122 and his target on MGM Resorts (MGM) to $35 from $34. Allen added that Las Vegas Sands remains his preferred play on Macau, as he thinks the Street is wrong in assuming it will lose market share.
MRK Merck
$79.40

(0.00%)

03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
03/13/19
CANT
03/13/19
NO CHANGE
Target $95
CANT
Overweight
Merck opportunity in China is underappreciated, says Cantor Fitzgerald
After taking a deeper look at the Chinese PD-1 market, Cantor Fitzgerald analyst Louise Chen believes it could equate to billions of sales that are not yet in the forecasts for Merck's Keytruda. She thinks the peak sales potential of PD-1s in China remains underappreciated. China's pharma market can grow to $225B by 2025, which would support a growing PD-1/PD-L1 market, Chen tells investors in a research note titled "Deep Dive into China: A Complicated but Underappreciated Opportunity." The analyst keeps an Overweight rating on Merck with a $95 price target.
03/11/19
WBLR
03/11/19
NO CHANGE
WBLR
Outperform
William Blair sum-of-the-parts analysis yields $19.80 value for Pfenex
The majority of Pfenex (PFNX) investor focus has been placed on lead asset PF708, the therapeutic equivalent product candidate to Forteo, William Blair analyst Andy Hsieh tells investors in a research note, citing his talks with clients. The analyst, however, sees "potential for significant value" from the company's collaboration with Jazz Pharmaceuticals (JAZZ). The deal with Jazz could provide patients with an alternative to Erwinaze/Erwinase, which currently suffers from significant supply constraints, and CRM197, a carrier protein that is incorporated as an adjuvant in several vaccine candidates, including Merck's (MRK) pneumococcal vaccine, V114, Hsieh writes. Based on these royalties, the analyst conducted a sum-of-the-parts analysis for Pfenex based on discounted cash flow, and the resulting net present value yielded a value of $19.80 per share. The stock closed Monday at $4.26. The analyst believes the company's "value-creating" catalysts this year, including milestone payment from Jazz for the successful tech transfer of PF743 and PF745 and the approval of PF708, coupled with his valuation analysis, affirm his bullish thesis. Hsieh believes Pfenex shares offer one of the best risk/reward symmetries in small-cap biotech and reiterates an Outperform rating on the name.
02/22/19
CANT
02/22/19
INITIATION
Target $95
CANT
Overweight
Merck initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen started Merck with an Overweight rating and $95 price target. The company's sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as its margin expansion opportunities, are underappreciated at current share levels, Chen tells investors in a research note. She expects upward earnings revisions and multiple expansion in 2019 to drive Merck shares higher.
CVX Chevron
$119.82

(0.00%)

04/15/19
MSCO
04/15/19
NO CHANGE
MSCO
Overweight
Chevron shares should be bought on Anadarko deal weakness, says Morgan Stanley
Morgan Stanley analyst Devin McDermott said he believes that Chevron's (CVX) agreement to acquire Anadarko (APC) is a "win-win for shareholders of both companies" given what he views as "clear strategic benefits and attractive accretion." Chevron was able to acquire the company "that offers the best strategic fit at what could prove to be the best relative valuation" ahead of what could be the start of a broader round of consolidation, contends McDermott, who recommends being a buyer of Chevron shares on the weakness seen after the deal was announced. In terms of who may be next, McDermott said he thinks Pioneer Natural (PXD), Concho Resources (CXO) and Parsley Energy (PE) could be potential targets for other oil majors.
04/15/19
04/15/19
DOWNGRADE
Target $65

Sector Perform
Anadarko downgraded to Sector Perform at RBC Capital on Chevron deal
As previously reported, RBC Capital analyst Scott Hanold downgraded Anadarko (APC) to Sector Perform and kept his $65 price target following the company's acquisition by Chevron (CVX). The analyst says he does not expect competing bids to emerge and believes that shareholders will accept the offer. Hanold adds that the deal came out from the "meaningful discount" for Anadarko shares related to the "combination of concern over political-driven changes in Colorado that could impact long-term development in the DJ Basin and the capital outlay required for the Mozambique LNG project upon sanction."
04/15/19
SBSH
04/15/19
NO CHANGE
Target $142
SBSH
Buy
Chevron price target raised to $142 from $135 at Citi
Citi analyst Alastair Syme raised his price target for Chevron (CVX) to $142 from $135 to reflect the company's acquisition of Anadarko Petroleum (APC). The analyst sees the acquisition as an "opportunistic deal" to acquire a "discounted resource that acts to lower the cost-curve position of the new entity." He keeps a Buy rating on Chevron shares.
04/15/19
MKMP
04/15/19
DOWNGRADE
Target $65
MKMP
Neutral
Anadarko downgraded to Neutral from Buy at MKM Partners
MKM Partners analyst John Gerdes downgraded Anadarko (APC) to Neutral from Buy and lowered his price target to $65 from $66 after its acquisition by Chevron (CVX). The analyst says the deal looks like a "near certainty" and also views its valuation at 6.1-times expected FY19 EBITDA as "full and fair". Gerdes adds that the business combination is "eminently logical", combining "asset/organization capabilities in the Delaware Basin, deep water Gulf of Mexico, and as to global LNG."
WFC Wells Fargo
$46.49

(0.00%)

04/15/19
04/15/19
DOWNGRADE

Neutral
Wells Fargo downgraded to Neutral at BofA/Merrill
As previously reported, BofA/Merrill downgraded Wells Fargo to Neutral from Buy and cut its price target to $50 from $57. Analyst Erika Najarian said there is a further deterioration in earning visibility and shares lack an upside catalysts until a new CEO is announced.
04/15/19
EVER
04/15/19
DOWNGRADE
EVER
In Line
Wells Fargo downgraded to In Line from Outperform at Evercore ISI
04/15/19
DBAB
04/15/19
NO CHANGE
Target $48
DBAB
Hold
Wells Fargo price target lowered to $48 from $54 at Deutsche Bank
Deutsche Bank analyst Matt O'Connor lowered his price target for Wells Fargo to $48 from $54 citing management's reduced outlook for net interest income and fewer share buybacks. The analyst keeps a Hold rating on Wells Fargo.
04/15/19
GSCO
04/15/19
DOWNGRADE
Target $48
GSCO
Neutral
Goldman downgrades Wells Fargo to Neutral, takes off Conviction list
Goldman Sachs analyst Richard Ramsden on Friday night downgraded Wells Fargo to Neutral from Buy and removed the shares from his firm's Americas Conviction List. The recent departure of Tim Sloan and questions over the time it will take to find a replacement, coupled with commentary on the Q1 earnings call around weaker than expected net interest income growth for 2019, has increased focus on Wells Fargo's ability to meet near term and longer term financial targets, Ramsden tells investors in a research note. The analyst expects the company's medium term operating leverage potential to be impacted by weaker net interest income growth. He cut his price target for the shares to $48 from $58.

TODAY'S FREE FLY STORIES

AEGN

Aegion

$19.44

-0.58 (-2.90%)

17:57
04/25/19
04/25
17:57
04/25/19
17:57
Hot Stocks
Aegion subsidiary awarded three contracts valued at $13M total »

Aegion announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

17:55
04/25/19
04/25
17:55
04/25/19
17:55
Hot Stocks
Amazon.com says will spend $800M in Q2 to move to one-day Prime delivery »

Says: Need to build out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

F

Ford

$9.41

-0.17 (-1.77%)

17:53
04/25/19
04/25
17:53
04/25/19
17:53
Hot Stocks
Ford CFO: Encouraged by progress made in China toward return to profitability »

Sees FY19 revenue growth,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

CIR

Circor

$34.53

-2 (-5.48%)

17:48
04/25/19
04/25
17:48
04/25/19
17:48
Earnings
Circor sees Q2 adjusted EPS 40c-48c, consensus 54c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

F

Ford

$9.41

-0.17 (-1.77%)

17:48
04/25/19
04/25
17:48
04/25/19
17:48
Hot Stocks
Ford CFO says Q1 market share declined to 5.9% from 6.5% »

Says EBIT and EBIT margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

CIR

Circor

$34.53

-2 (-5.48%)

17:46
04/25/19
04/25
17:46
04/25/19
17:46
Earnings
Circor reports Q1 adjusted EPS 38c, consensus 37c »

Reports Q1 revenue $270M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

F

Ford

$9.41

-0.17 (-1.77%)

17:45
04/25/19
04/25
17:45
04/25/19
17:45
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford sees over $1B in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

ARGO

Argo Group

$74.21

-0.245 (-0.33%)

17:43
04/25/19
04/25
17:43
04/25/19
17:43
Upgrade
Argo Group rating change at William Blair »

Argo Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 11

    Jun

ILMN

Illumina

$318.91

4.47 (1.42%)

17:36
04/25/19
04/25
17:36
04/25/19
17:36
Earnings
Illumina raises FY19 adj. EPS view to $6.63-$6.73 from $6.50-$6.60 »

Consensus $6.53. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

HTH

Hilltop Holdings

$19.90

-0.19 (-0.95%)

17:35
04/25/19
04/25
17:35
04/25/19
17:35
Earnings
Hilltop Holdings reports Q1 EPS 41c, consensus 26c »

Hilltop's annualized…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

F

Ford

$9.41

-0.17 (-1.77%)

17:35
04/25/19
04/25
17:35
04/25/19
17:35
Hot Stocks
Ford backs long-term revenue growth target view exceeding global GDP »

Backs FY19 long-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

ILMN

Illumina

$318.91

4.47 (1.42%)

17:32
04/25/19
04/25
17:32
04/25/19
17:32
Earnings
Illumina reports Q1 adj. EPS $1.60, consensus $1.34 »

Reports Q1 revenue $846M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

GIB

CGI Group

$71.16

0.36 (0.51%)

17:30
04/25/19
04/25
17:30
04/25/19
17:30
Downgrade
CGI Group rating change at CIBC »

CGI Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

ARGO

Argo Group

$74.21

-0.245 (-0.33%)

17:30
04/25/19
04/25
17:30
04/25/19
17:30
Upgrade
Argo Group rating change at William Blair »

Argo Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 11

    Jun

SBUX

Starbucks

$77.07

0.65 (0.85%)

, NSRGY

Nestle

$0.00

(0.00%)

17:30
04/25/19
04/25
17:30
04/25/19
17:30
Hot Stocks
Starbucks sees FY19 adjusted effective tax rate 19%-21% »

Says Nestle alliance…

SBUX

Starbucks

$77.07

0.65 (0.85%)

NSRGY

Nestle

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

GCI

Gannett

$9.26

-0.11 (-1.17%)

17:29
04/25/19
04/25
17:29
04/25/19
17:29
Hot Stocks
Gannett still urges holders to vote 'FOR ALL' of its director nominees »

Gannett issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 16

    May

PRA

ProAssurance

$36.08

0.08 (0.22%)

17:28
04/25/19
04/25
17:28
04/25/19
17:28
Hot Stocks
ProAssurance concerned over loss trends in healthcare professional liability »

"Our concern about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 22

    May

  • 22

    May

NCR

NCR Corp.

$28.62

-0.755 (-2.57%)

17:27
04/25/19
04/25
17:27
04/25/19
17:27
Syndicate
NCR Corp. files to sell 20.39M shares of common stock »

Also files to sell up to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

PRA

ProAssurance

$36.08

0.08 (0.22%)

17:24
04/25/19
04/25
17:24
04/25/19
17:24
Earnings
ProAssurance reports Q1 EPS 8c, consensus 35c »

Reports Q1 revenue $269M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 22

    May

  • 22

    May

MRK

Merck

$76.33

1.6 (2.14%)

17:22
04/25/19
04/25
17:22
04/25/19
17:22
Hot Stocks
Merck provides update on Phase 3 KEYNOTE-062 trial »

Merck announced topline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    May

  • 04

    May

  • 06

    May

  • 18

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 06

    Aug

  • 20

    Sep

ACB

Aurora Cannabis

$9.07

-0.045 (-0.49%)

, CGC

Canopy Growth

$48.20

-0.13 (-0.27%)

17:22
04/25/19
04/25
17:22
04/25/19
17:22
Initiation
Aurora Cannabis, Canopy Growth, HEXO Corp, Constellation Brands, AB InBev, Altria Group, Walgreens Boots Alliance, CVS Health, Rite Aid initiated  »

Desjardins initiates HEXO…

ACB

Aurora Cannabis

$9.07

-0.045 (-0.49%)

CGC

Canopy Growth

$48.20

-0.13 (-0.27%)

HEXO

HEXO Corp

$7.14

0.01 (0.14%)

STZ

Constellation Brands

$212.19

2.12 (1.01%)

BUD

AB InBev

$86.63

-1.57 (-1.78%)

MO

Altria Group

$51.42

-3.28 (-6.00%)

WBA

Walgreens Boots Alliance

$52.67

-0.8 (-1.50%)

CVS

CVS Health

$53.24

0.31 (0.59%)

RAD

Rite Aid

$8.98

-0.64 (-6.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 07

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 18

    Jun

DRQ

Dril-Quip

$43.59

-0.87 (-1.96%)

17:21
04/25/19
04/25
17:21
04/25/19
17:21
Earnings
Dril-Quip sees Q2 revenue at high end of $90M-$100M, consensus $95M »

Raises Q2 expectations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SBUX

Starbucks

$77.07

0.65 (0.85%)

17:20
04/25/19
04/25
17:20
04/25/19
17:20
Hot Stocks
Starbucks says on track to deliver on capital return commitment »

Says on track to deliver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

DRQ

Dril-Quip

$43.59

-0.87 (-1.96%)

17:20
04/25/19
04/25
17:20
04/25/19
17:20
Earnings
Dril-Quip reports Q1 EPS (17c), consensus (6c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SBUX

Starbucks

$77.07

0.65 (0.85%)

17:17
04/25/19
04/25
17:17
04/25/19
17:17
Hot Stocks
Starbucks says 'well-positioned' for long-term growth in China »

Sees 6,000 China stores…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.